As per our report, the size of the global monoclonal antibodies market was worth USD 39.10 Billion in 2021. This figure is estimated to be growing at a CAGR of 5.30% and will reach USD 50.62 Billion by 2026.
In biochemistry and molecular biology, monoclonal antibodies play an important role in detecting or purifying substances. These are derived from identical immune cells and can easily bind to a particular antigen. Hybridoma technology is designing monoclonal antibodies where will enhance the immunity system naturally. It is approved by the U.S Food and Drug Administration (FDA) as it is an innovative product in molecular biology for disease treatment. Many global companies are focusing on developing molecular agents for the treatment of various diseases like cancer.
MARKET DRIVERS:
Increasing incidences of chronic diseases such as cancer, diabetes, and others worldwide is undoubtedly a key factor for the worldwide monoclonal antibodies market to grow.
The rise in the demand to ensure quality services in healthcare is additionally accelerating the need of the market. Also, the invention of new applications in monoclonal antibodies significantly influences the growth rate of this market. The rise in investments in healthcare infrastructure improvement is likely to boost the global mABs market demand. The development of new molecules is expected to play a prominent role in the future of the market due to the cost-effectiveness of this technology.
The advancement of genomics research and development activities and the emergence of technologically advanced genetic platforms, such as the next-generation sequencing, have contributed significantly to the market and helped the existing companies in the global mABs market grow further.
The emergence of advanced technology and the launch of innovative products in the biotechnology field, and growth in the economy in developed and developing countries are surging the demand of the monoclonal antibodies market. Growing knowledge over genomics and trend towards next-generation sequencing and ease in the availability of various resources used in the research centers fuel the demand of the market. The rise in awareness over the therapies and other biological parameters impacts the growth of the market.
MARKET RESTRAINTS:
However, less availability of raw materials used for the manufacturing of drugs restrains the demand of the market. Lack of sufficient knowledge in rural areas is slowly hindering the growth rate of the global monoclonal antibodies market.
One of the other major challenging factors for the monoclonal antibodies market is the shortage of skilled labor. It is due to fewer training programs in the biotechnology field. The equipment used in the laboratories is high in cost, where small-scale organizations cannot afford them, which is also one of the factors impeding the demand of the mABs market.
Impact of COVID-19 on the global monoclonal antibodies market:
The outburst of COVID-19 has brought the world to a standstill. This health crisis has brought an unprecedented impact on businesses in every sector, including the healthcare sector. The COVID-19 impact has positively influenced the monoclonal antibodies market as these antibodies prevent and treat early infections of COVID-19. Many companies are in a race to find an efficient vaccine to treat novel coronavirus disease with the help of monoclonal antibodies. Government organizations support the researchers by approving the emergency utilization of the new products to treat this disease. Many of the monoclonal antibodies licensed or in the development for other diseases are in the clinical trials to check whether they affect COVID-19 patients.
REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2021 to 2026 |
|
Base Year |
2020 |
|
Forecast Period |
2021 to 2026 |
|
Segments Covered |
By Source, Indication, End User, Application, and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Covered |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
This research report on Global Monoclonal Antibodies Market has been segmented and sub-segmented based on the source, indication, end-user, application, and region.
Monoclonal Antibodies Market - By Source:
Based on the source, the murine segment holds the highest shares of the global monoclonal antibodies market, whereas chimeric is to have the highest growth rate in the coming years. An increasing number of people suffering from various health disorders is a specific factor for this segment to grow.
The Humanized monoclonal segment is one of the most lucrative segments among all and is expected to grow at a healthy rate during the forecast period. Extensive adoption of innovative techniques for the treatment of various diseases such as cancer and inflammatory diseases is propelling the demand of this segment. Progressive genetic engineering technology engaged in its production is one of the significant factors driving the segment demand.
The human monoclonal antibodies segment is to have rapid growth between 2020 to 2025.
Monoclonal Antibodies Market - By Indication:
Based on indication, the cancer disease segment is ruling with dominant shares of the global mABs market. Adopting sedentary lifestyles and food habits changes are some of the attributes for the cancer diseases category to grow. It is expected that this segment will continue its dominance throughout the forecast period. The segment growth is majorly driven by the high increase in the incidence of cancer and healthcare reimbursement policies. Intensifying drug pipeline integrated with treatment approvals and clinical trials is projected to generate profitable growth opportunities in the monoclonal antibodies market.
Monoclonal Antibodies Market - By End-User:
Based on end-user, Hospitals/clinics have the most significant shares in the market by increasing healthcare centers and clinics' scale. Besides, the growing geriatric population is enhancing the growth rate of the market. The increasing patient population and growing chronic diseases in patients are leveling up the demand of this segment. The segment holds 35.0% of the hospital end-user segment. This segment is driven by increasing occurrences of chronic ailments, growing healthcare expenses, and rising awareness levels among the patient population related to alternative treatments. Extensive adoption of numerous various diseases is to foster the growing demand in the market.
Monoclonal Antibodies Market - By Application:
Based on the application, the medical segment is holding dominant shares of the global monoclonal antibodies market due to a rise in the number of research and development activities.
the ELISA segment fosters the monoclonal antibody market during the analysis period.
Monoclonal Antibodies Market – By Region:
Geographically, North America is dominating the global market due to the well-established health care infrastructure in this region, the increased importance given to state infection control and management, and the growing prevalence of lifestyle-related health issues. The market will continue to grow during the forecast period, owing to amplified public investments for cancer research and technological development.
Asia-Pacific market segment is also anticipated to increase significantly due to improved lifestyles of people and increasing awareness about mAbs among patients, advanced research, and development costs. Due to the lack of penetration, the Asia Pacific market has a high potential to grow during the forecast period.
KEY MARKET PARTICIPANTS & SHARE INSIGHTS:
Companies leading the global monoclonal antibodies market profiled in the report are GlaxoSmithKline PLC, Novartis AG, Pfizer Inc., Thermo Fisher Scientific Inc., Eli Lilly and Company, Seattle Genetics, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., And Shanghai Junshi Bioscience Co., Ltd.
RECENT DEVELOPMENTS:
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Source
5.1.1 Murine
5.1.2 Chimeric
5.1.3 Humanized
5.1.4 Human
5.2 By Indication
5.2.1 Cancer
5.2.1.1 Blood Cancer
5.2.1.2 Breast Cancer
5.2.1.3 Colorectal Cancer
5.2.1.4 Lung Cancer
5.2.1.5 Pancreatic Cancer
5.2.1.6 Others
5.2.2 Autoimmune Diseases
5.2.3 Infectious Diseases
5.2.4 Cardiovascular Diseases
5.2.5 CNS Disorders
5.2.6 Others (Inflammatory, Microbial Diseases, & Other)
5.3 End User
5.3.1 Hospitals/Clinics
5.3.2 Research Institute
5.3.3 Diagnostic Laboratories
5.4 Application
5.4.1 Medical
5.4.2 Experimental
5.4.2.1 Western Blot
5.4.2.2 ELISA
5.4.2.3 Radioimmune Assays
5.4.2.4 Immunofluorescence
5.4.2.5 Other (Immunohistochemistry, Immunoprecipitation, & Immunocytochemistry)
6. Geographical Analysis
6.1 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.2 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.3 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 South Korea
6.3.6 Australia
6.4 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Argentina
6.4.4 Mexico
6.5 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7. Pipeline Product Analysis
7.1 Overview
7.2 Pipeline Development Landscape
7.3 Molecular Targets in the Pipeline
7.4 Clinical Trials
7.4.1 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.2 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target
7.5 Key Trends in Monoclonal Antibodies Development
7.5.1 Targeted Therapies
7.6 Promising Monoclonal Antibodies in Pipeline
7.7 Heat Map of Safety and Efficacy for Pipeline and Marketed Monoclonal Antibodies
8.Strategic Analysis
8.1 PESTLE analysis
8.1.1 Political
8.1.2 Economic
8.1.3 Social
8.1.4 Technological
8.1.5 Legal
8.1.6 Environmental
8.2 Porter’s Five analysis
8.2.1 Bargaining Power of Suppliers
8.2.2 Bargaining Power of Consumers
8.2.3 Threat of New Entrants
8.2.4 Threat of Substitute Products and Services
8.2.5 Competitive Rivalry within the Industry
9.Market Leaders' Analysis
9.1 GlaxoSmithKline plc (U.K.)
9.1.1 Overview
9.1.2 Product Analysis
9.1.3 Financial analysis
9.1.4 Recent Developments
9.1.5 SWOT analysis
9.1.6 Analyst View
9.2 Novartis AG (Switzerland)
9.3 Pfizer Inc. (U.S.)
9.4 Thermo Fisher Scientific Inc. (U.S.)
9.5 Eli Lilly and Company (U.S.)
9.6 Seattle Genetics (U.S.)
9.7 Bristol-Myers Squibb (U.S.)
9.8 F. Hoffmann-La Roche Ltd. (Switzerland)
9.9 Biogen Inc.(U.S.)
10.Competitive Landscape
10.1 Market share analysis
10.2 Merger and Acquisition Analysis
10.3 Agreements, collaborations and Joint Ventures
10.4 New Product Launches
11.Market Outlook & Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
